EMAIL DIGESTS
Daily
Every morning
Weekly
Sunday recap
The Novartis Venture Fund invests in life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Protego Biopharma Lands $130 Million Oversubscribed Series B Financing
FoRx Therapeutics Raises USD50M in Series A Financing
EpiBiologics Closes $107M Series B
Protego Biopharma Raises $130M in Series B Financing
Protego Biopharma Secures $130M Series B Funding
Protego Biopharma Secures $130M Series B Funding Led by Novartis Venture Fund
EpiBiologics Raises $107M in Series B to Advance Protein-Degrading Cancer Drug
FoRx Therapeutics Secures $50M Series A to Advance Precision Cancer Drug